RT Journal Article
SR Electronic
T1 Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Detection in Cancer Patients: A Prognostic Marker For Lung Metastases from Solid Malignancies
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1411
OP 1415
VO 28
IS 2B
A1 ELENI M. KARAPANAGIOTOU
A1 EMILIA PELEKANOU
A1 ADRIANNI CHARPIDOU
A1 THOMAS TSAGANOS
A1 VALSAMO ANAGNOSTOU
A1 DIAMANTIS PLACHOURAS
A1 EVANGELOS J. GIAMARELLOS-BOURBOULIS
A1 KOSTAS N. SYRIGOS
YR 2008
UL http://ar.iiarjournals.org/content/28/2B/1411.abstract
AB The aim of the study was to evaluate the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) levels in breast, lung and colorectal cancer patients in correlation with clinical variables. Patients and Methods: A total of 59 patients with a median age of 64 years and histologically confirmed breast 14, colorectal 15 or lung cancer 30 were evaluated. Five patients with breast cancer, 7 patients with colorectal cancer and 8 patients with lung cancer had lung metastases. Blood was collected upon enrolment, centrifuged and the serum kept at -80°C until assayed for sTREM-1. The estimation of sTREM-1 was performed by a crude enzyme immunoabsorbent assay. Results: High levels of sTREM-1 were observed in 50% of breast cancer, 33.3% of Small Cell Lung carcinoma (SCLC), 26.7% of colorectal cancer and 13.3% of Non Small Cell Lung Carcinoma (NSCLC) patients. sTREM-1 expression showed a correlation to the site of metastases. Higher concentrations were observed in the absence of lung metastases (p=0.019). Discussion: The novel mediator sTREM-1 may be a prognostic marker for the detection of lung metastases in metastatic and locally advanced solid tumors. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved